Taiwan Liposome Company, Ltd

General Information
Business:

 

(Note: “Our common shares are currently listed on the Taipei Exchange. On April 12, 2018, the last reported sale price of our common shares on the Taipei Exchange was NT$109.00 per share, or approximately $3.73 per share, equivalent to a price of $7.46 per ADS, based on an exchange rate of NT$29.29 to $1.00. Assuming an initial public offering price of $7.46 per ADS.”)

We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). We believe that our extensive experience with liposome science allows us to combine onset speed and benefit duration, and to improve API concentrations at target tissues while decreasing unwanted systemic exposures.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 168
Founded: 1997
Contact Information
Address 11F-1, No. 3 Yuanqu Street, Nangang District, Taipei City, Taiwan 11503, Republic of China
Phone Number +886 2 2655 7377
Web Address http://www.tlcbio.com
View Prospectus: Taiwan Liposome Company, Ltd
Financial Information
Market Cap $244.6mil
Revenues $1.7 mil (last 12 months)
Net Income $-29.5 mil (last 12 months)
IPO Profile
Symbol TLC
Exchange NASDAQ
Shares (millions): 4.7
Price range $7.46 - $7.46
Est. $ Volume $36.3 mil
Manager / Joint Managers Cantor
CO-Managers CLSA/ H.C. Wainwright/ Janney Montgomery Scott/ Laidlaw & Company (UK) Ltd.
Expected To Trade: 4/26/2018
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change